Uncaria rhynchophylla induces angiogenesis in vitro and in vivo.
Angiogenesis consists of the proliferation, migration, and differentiation of endothelial cells, and angiogenic factors and matrix protein interactions modulate this process. The aim of this study was to determine the angiogenic properties of Uncaria rhynchophylla. Uncaria rhynchophylla significantly enhanced human umbilical vein endothelial cells (HUVECs) proliferation in a dose-dependent manner. Neutralization of vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) by monoclonal antibody suppressed the Uncaria rhynchophylla stimulatory effect on proliferation. In addition, Uncaria rhynchophylla significantly increased chemotactic-migration on gelatin and tubular structures on Matrigel of HUVECs in a dose-dependent manner. Interestingly, Uncaria rhynchophylla dose-dependently increased VEGF, and bFGF gene expression and protein secretion of HUVEC. The angiogenic activity of Uncaria rhynchophylla was confirmed using an in vivo Matrigel angiogenesis model, showing promotion of blood vessel formation. These results suggest that Uncaria rhynchophylla could potentially used to accelerate vascular wound healing or to promote the growth of collateral blood vessel in ischemic tissues.
Choi
Do-Young
DY
Department of Acupuncture & Moxibustion, College of Oriental Medicine, 1 Hoegidong, Dongdaemungu, Seoul 130-701, Korea.
Huh
Jeong-Eun
JE
Lee
Jae-Dong
JD
Cho
Eun-Mi
EM
Baek
Yong-Hyeon
YH
Yang
Ha-Ru
HR
Cho
Yoon-Je
YJ
Kim
Kang-Il
KI
Kim
Deog-Yoon
DY
Park
Dong-Suk
DS
D043925:Angiogenesis Inducing Agents / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000008:administration & dosage; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D042783:Endothelial Cells / Q000187:drug effects / Q000648:ultrastructure; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006454:Hemoglobins; D006801:Humans; D007797:Laminin / Q000008:administration & dosage; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010936:Plant Extracts / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology; D011509:Proteoglycans / Q000008:administration & dosage; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000648:ultrastructure; D032070:Uncaria / Q000737:chemistry*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology
D043925:Angiogenesis Inducing Agents; D001672:Biocompatible Materials; D004338:Drug Combinations; D006454:Hemoglobins; D007797:Laminin; D010936:Plant Extracts; D011509:Proteoglycans; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; C059485:matrigel; D003094:Collagen